Xromi

Dosage of Hydroxyurea is highly individualized and is typically based on the patient's actual or ideal body weight, whichever is less. Healthcare providers aim to find the 'maximum tolerated dose' that provides therapeutic benefit without causing severe bone marrow suppression.

• Sickle Cell Anemia: The initial dose is usually 15 mg/kg once daily. The dose may be increased by 5 mg/kg every 8 to 12 weeks, provided blood counts remain within acceptable ranges. The maximum recommended dose is 35 mg/kg/day.
• Solid Tumors/Cancers: Intermittent therapy may involve 80 mg/kg administered as a single dose every third day. Continuous therapy may involve 20 to 30 mg/kg administered as a single daily dose.
• Chronic Myeloid Leukemia: Doses typically range from 20 mg/kg to 30 mg/kg daily as a single dose.

Hydroxyurea is FDA-approved for use in pediatric patients aged 2 years and older for sickle cell anemia.

• Initial Pediatric Dose: Similar to adults, the starting dose is generally 20 mg/kg once daily.
• Titration: The dose is adjusted based on the child's weight gain and blood count response. Healthcare providers monitor growth and development closely during treatment.
• Safety: Hydroxyurea has not been formally studied in children under the age of 2 for sickle cell disease, though some specialized centers may use it under strict protocols.

Renal Impairment

Because the kidneys excrete a significant portion of Hydroxyurea, patients with decreased kidney function require lower doses. For patients with a Creatinine Clearance (CrCl) of less than 60 mL/min, healthcare providers typically reduce the starting dose by 50%. Patients on hemodialysis may receive a dose following the dialysis session.

Hepatic Impairment

There are no specific dose adjustment guidelines for patients with liver disease; however, close monitoring of liver function tests is recommended, as the drug undergoes hepatic metabolism.

Elderly Patients

Older adults are more likely to have decreased renal function. Therefore, healthcare providers usually start at the lower end of the dosing range and monitor kidney function frequently.

1. 1Consistency: Take the medication at the same time every day. It can be taken with or without food, but consistency is key to maintaining stable blood levels.
2. 2Swallow Whole: Capsules and tablets should ideally be swallowed whole. If a patient cannot swallow the capsule, the contents can be emptied into a glass of water and swallowed immediately. However, because Hydroxyurea is a cytotoxic (cell-killing) drug, the powder should not be inhaled or allowed to touch the skin or mucous membranes.
3. 3Hydration: It is vital to drink plenty of fluids (8-10 glasses of water per day) while taking Hydroxyurea to help the kidneys flush the medication and prevent uric acid buildup.
4. 4Handling: Caregivers should wear disposable gloves when handling the medication or the bottles. If the powder from a broken capsule spills, it should be wiped up with a damp disposable towel and discarded in a closed container, such as a plastic bag.
5. 5Storage: Store at room temperature (68°F to 77°F) in a dry place away from direct sunlight.

If a dose is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next dose, the missed dose should be skipped. Never double the dose to 'catch up,' as this significantly increases the risk of severe bone marrow toxicity.

Signs of an acute Hydroxyurea overdose may include acute mucocutaneous toxicity (severe sores in the mouth and throat), soreness, violet erythema (purple skin rash), edema (swelling) on the palms and soles followed by scaling of the hands and feet, severe hyperpigmentation of the skin, and severe bone marrow suppression. In case of suspected overdose, contact a Poison Control Center or seek emergency medical attention immediately. Treatment is primarily supportive.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this can lead to a rebound increase in blood counts or a return of sickle cell crises.

Hydroxyurea is a potent medication that affects rapidly dividing cells, leading to several common side effects. Most patients will experience at least one of the following:

• Myelosuppression: This is the most significant side effect. It involves a decrease in the production of blood cells in the bone marrow. This includes Leukopenia (low white blood cells), which increases infection risk; Anemia (low red blood cells), causing fatigue and shortness of breath; and Thrombocytopenia (low platelets), which can cause easy bruising or bleeding.
• Gastrointestinal Distress: Nausea, vomiting, and diarrhea are frequent, especially when starting therapy. Stomatitis (inflammation of the mouth and lips) or mouth ulcers may also occur.
• Skin Changes: Hyperpigmentation (darkening) of the skin and nails is very common. Patients may notice vertical bands on their fingernails or a general darkening of the skin in areas exposed to the sun.
• Hair Thinning: While complete hair loss (alopecia) is rare, many patients experience noticeable thinning of the hair.

• Dizziness and Headache: Some patients report neurological symptoms, including a feeling of lightheadedness or persistent headaches.
• Elevated Liver Enzymes: Hydroxyurea can cause temporary inflammation of the liver, detectable through blood tests (ALT, AST, and Bilirubin).
• Fever and Chills: Often occurring shortly after a dose, sometimes referred to as 'drug fever.'
• Weight Gain or Loss: Changes in appetite can lead to fluctuations in body weight.

• Pulmonary Toxicity: Rarely, Hydroxyurea can cause interstitial lung disease, characterized by a dry cough and progressive shortness of breath.
• Acute Leukemia: Long-term use of Hydroxyurea has been associated with the development of secondary leukemias in patients treated for myeloproliferative disorders.
• Gastrointestinal Ulceration: Severe irritation of the stomach or intestinal lining.

> Warning: Stop taking Hydroxyurea and call your doctor immediately if you experience any of these serious symptoms:

• Signs of Infection: Fever over 100.4°F (38°C), chills, sore throat, or productive cough. Because Hydroxyurea lowers white blood cells, infections can become life-threatening rapidly.
• Unusual Bleeding: Bloody stools, black/tarry stools, coughing up blood, or heavy menstrual bleeding.
• Cutaneous Vasculitic Ulcerations: These are painful, open sores that typically appear on the lower legs or ankles. They are difficult to heal and may require discontinuation of the drug.
• Pancreatitis: Severe pain in the upper stomach spreading to the back, nausea, and vomiting. This is especially a risk if taken with certain HIV medications.
• Hepatotoxicity: Yellowing of the eyes or skin (jaundice), dark urine, and extreme fatigue.

• Secondary Malignancies: There is an increased risk of developing skin cancers (squamous cell and basal cell carcinoma). Patients must use sun protection and have regular skin exams.
• Fertility Issues: Hydroxyurea can lower sperm counts in men (oligospermia), which may or may not be reversible after stopping the drug. Its effects on female fertility are less clear but require caution.
• Chronic Leg Ulcers: In some patients, long-term use leads to the development of painful ulcers near the ankles that only resolve when the medication is stopped.

Hydroxyurea carries an FDA Black Box Warning, the most serious type of warning.

1. 1Myelosuppression: Hydroxyurea may cause severe and sometimes life-threatening low blood counts. Treatment should not be started if bone marrow function is significantly depressed. Healthcare providers must monitor blood counts weekly or bi-weekly.
2. 2Carcinogenicity: Hydroxyurea is genotoxic and is a known human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, secondary leukemias have been reported. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Patients should protect skin from sun exposure and be monitored for malignancies.

Report any unusual symptoms to your healthcare provider immediately. Regular laboratory monitoring is the only way to catch many of these side effects before they become dangerous.

Hydroxyurea is a high-alert medication. It is a cytotoxic agent that must be handled with extreme care. Patients must be committed to frequent blood tests, as this is the only way to ensure the dose is effective without being toxic. It is also essential to inform all healthcare providers, including dentists and surgeons, that you are taking Hydroxyurea, as it can affect healing and the risk of infection.

According to the FDA-approved labeling (2024), Hydroxyurea carries the following boxed warnings:

• Severe Myelosuppression: The drug can cause a profound drop in white blood cells (neutropenia) and platelets (thrombocytopenia). This increases the risk of fatal infections and hemorrhages. Therapy must be interrupted if counts fall below specific thresholds.
• Malignancies: There is a confirmed risk of secondary cancers, particularly leukemia and skin cancers. This risk is cumulative and associated with long-term use.

• Cutaneous Vasculitis: Patients with myeloproliferative disorders may develop vascular ulcers and gangrene. This is most common in those also taking interferon therapy. If ulcers develop, the drug usually must be discontinued.
• Vaccinations: Avoid 'live' vaccines (such as the MMR or nasal flu vaccine) while taking Hydroxyurea. The drug weakens the immune system, and the vaccine could cause the disease it is intended to prevent. Inactive (killed) vaccines may be less effective.
• Tumor Lysis Syndrome: In patients with high tumor burdens or very high white cell counts, rapid cell kill can lead to a surge in uric acid, potentially damaging the kidneys. Hydration and medications like allopurinol may be used to prevent this.
• Erythrocyte Abnormalities: Hydroxyurea causes macrocytosis (enlarged red blood cells), which can interfere with certain lab tests, such as the MCV (mean corpuscular volume). This is a normal effect of the drug and does not necessarily indicate Vitamin B12 deficiency.

Patients on Hydroxyurea require a rigorous monitoring schedule:

• Complete Blood Count (CBC): Typically performed every 1 to 2 weeks during the dose-titration phase and every 4 to 8 weeks once a stable dose is reached.
• Renal Function: Serum creatinine and BUN should be checked periodically to ensure the kidneys are clearing the drug.
• Liver Function: Periodic testing of AST, ALT, and bilirubin.
• Uric Acid: Monitored to prevent gout or kidney stones.
• Skin Exams: Annual or semi-annual checks by a dermatologist to screen for skin cancer.

Hydroxyurea may cause dizziness, drowsiness, or confusion in some patients. Do not drive or operate heavy machinery until you know how the medication affects you. These symptoms are more common when starting the drug or increasing the dose.

Alcohol should be used with extreme caution. Both alcohol and Hydroxyurea are processed by the liver, and combining them can increase the risk of hepatotoxicity. Furthermore, alcohol can contribute to dehydration, which increases the risk of Hydroxyurea-related kidney strain.

Do not stop taking Hydroxyurea abruptly unless directed by a physician (e.g., in the case of a severe side effect). In patients with CML or polycythemia vera, stopping the drug can lead to a 'rebound' effect where blood counts rise rapidly to dangerous levels. In sickle cell patients, stopping the drug will lead to a gradual loss of fetal hemoglobin and a return of painful crises.

> Important: Discuss all your medical conditions, especially kidney disease, liver disease, or a history of gout, with your healthcare provider before starting Hydroxyurea.

• Live Vaccines: As noted, live attenuated vaccines (e.g., Yellow Fever, Varicella, Rotavirus) are contraindicated due to the risk of disseminated vaccine-related infection in an immunocompromised host.
• Didanosine (ddI) and Stavudine (d4T): These HIV medications, when combined with Hydroxyurea, significantly increase the risk of fatal pancreatitis, severe hepatotoxicity, and peripheral neuropathy. This combination should be avoided entirely.

• Interferons: Combining Hydroxyurea with interferon (often used for hepatitis or certain cancers) increases the risk of cutaneous vasculitis (painful skin ulcers) and gangrene. Healthcare providers monitor the skin of the lower extremities very closely in these patients.
• Cytotoxic Chemotherapy: Taking Hydroxyurea with other chemotherapy agents (like cytarabine or fluorouracil) can lead to additive bone marrow suppression. This requires more frequent CBC monitoring.
• Clozapine: Both drugs can cause severe neutropenia (low white blood cells). Combining them significantly elevates the risk of agranulocytosis, a life-threatening lack of white blood cells.

• Uricosuric Agents (e.g., Probenecid): Hydroxyurea can increase uric acid levels in the blood. Medications used to treat gout may need dosage adjustments to remain effective.
• Urea-containing products: Since Hydroxyurea is partially metabolized to urea, it may interfere with certain tests or treatments involving urea.

• High-Fat Meals: While food does not stop the absorption of Hydroxyurea, a very high-fat meal might delay the time it takes for the drug to reach its peak concentration in the blood. It is best to take the medication in a consistent manner relative to meals.
• Hydration Status: While not a direct interaction with a specific food, dehydration significantly increases the risk of toxicity. Patients should avoid excessive caffeine, which can act as a diuretic.

• St. John's Wort: This supplement can induce certain metabolic pathways. While not directly linked to CYP3A4, it can generally complicate the metabolic profile of many drugs and should be used with caution.
• Antioxidant Supplements: High doses of antioxidants (like Vitamin C or E) might theoretically interfere with the free-radical-based mechanism by which Hydroxyurea inhibits ribonucleotide reductase. Consult a doctor before taking high-dose vitamins.
• Echinacea: This herb is often used to stimulate the immune system, which may counteract the intended immunosuppressive effects of Hydroxyurea in certain conditions.

• Serum Uric Acid: Hydroxyurea may falsely elevate or naturally increase uric acid levels.
• MCV (Mean Corpuscular Volume): Hydroxyurea almost always increases the size of red blood cells (macrocytosis). This is a sign the drug is working and should not be confused with megaloblastic anemia caused by B12 or folate deficiency.
• Creatinine and Urea: The drug may interfere with some enzymatic assays for these substances, leading to inaccurate results.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete and updated list is vital for your safety.

There are several scenarios where Hydroxyurea must never be used due to the extreme risk of harm:

1. 1Hypersensitivity: Any patient with a known severe allergy or anaphylactic reaction to Hydroxyurea or any component of the formulation must not take the drug.
2. 2Severe Bone Marrow Suppression: Hydroxyurea is contraindicated if the patient's baseline blood counts are dangerously low. Specifically, if the Neutrophil count is less than 2,000/mm³ or the Platelet count is less than 100,000/mm³, the drug should not be started or must be held until counts recover.
3. 3Pregnancy: Hydroxyurea is a known teratogen (causes birth defects). It is contraindicated in pregnant women as it can cause fetal death or severe malformations. Women of childbearing age must use effective contraception.
4. 4Breastfeeding: The drug is excreted in human milk and has the potential for serious adverse reactions in nursing infants. Breastfeeding is contraindicated during treatment.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Renal Insufficiency: Because the drug is renally cleared, patients with end-stage renal disease require extreme caution and significant dose reductions.
• Active Infection: Since Hydroxyurea lowers white blood cell counts, starting the drug during an active, severe infection could prevent the body from fighting the illness.
• Previous Radiation or Chemotherapy: Patients who have recently received other DNA-damaging therapies are at a much higher risk for severe, prolonged bone marrow suppression and secondary cancers.
• Liver Disease: Patients with significant hepatic impairment may not metabolize the drug efficiently, increasing the risk of systemic toxicity.

There is no well-documented cross-sensitivity between Hydroxyurea and other common drug classes. However, patients who have had severe reactions to other antimetabolites (like Fluorouracil or Methotrexate) should be monitored closely, as their bodies may be particularly sensitive to the disruption of DNA synthesis pathways.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of gout, kidney stones, or skin cancer, before prescribing Hydroxyurea.

Hydroxyurea is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. It is known to be embryotoxic and teratogenic in all animal species tested.

• Risks: Exposure during the first trimester is particularly dangerous, potentially leading to major organ malformations.
• Contraception: Females of reproductive potential should use effective contraception during therapy and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during and for at least 1 year after the final dose (due to the drug's effect on sperm).

Hydroxyurea is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants—including the risk of cancer and immune suppression—a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most clinical guidelines recommend against breastfeeding while taking this medication.

Hydroxyurea (specifically the brand Siklos) is approved for use in children 2 years of age and older with sickle cell anemia.

• Benefits: Clinical trials have shown that it significantly reduces the rate of vaso-occlusive crises and hospitalizations in children.
• Concerns: There are theoretical concerns regarding the effect of long-term Hydroxyurea on growth, pubertal development, and future fertility. However, many years of clinical use have shown that the benefits of preventing organ damage from sickle cell disease usually outweigh these risks. Pediatric patients require very close monitoring by a pediatric hematologist.

Clinical studies of Hydroxyurea did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

• Renal Risk: Older patients are more likely to have decreased renal function. Since the risk of toxic reactions to this drug is greater in patients with impaired renal function, dose selection should be cautious, usually starting at the low end of the dosing range.
• Polypharmacy: The elderly are often taking multiple medications, increasing the risk of drug-drug interactions.

As the kidneys clear 40% of the drug, renal function is the primary determinant of Hydroxyurea clearance.

• Mild to Moderate: Doses should be reduced.
• Severe (CrCl < 30 mL/min): Requires a 50% reduction in the starting dose.
• Dialysis: Patients on dialysis should receive their dose after the dialysis procedure, as the treatment removes the drug from the blood.

While there are no specific dose-adjustment formulas for liver disease, Hydroxyurea is partially metabolized in the liver. Patients with a Child-Pugh score indicating moderate to severe liver disease should be monitored more frequently for signs of toxicity, particularly gastrointestinal side effects and further elevations in liver enzymes.

> Important: Special populations require individualized medical assessment. Always disclose your full health status to your medical team.

Hydroxyurea is a cell-cycle-specific agent that acts in the S-phase. Its primary molecular target is the enzyme ribonucleotide reductase (RR). This enzyme consists of two subunits, R1 and R2. Hydroxyurea specifically targets the R2 subunit by quenching a tyrosyl free radical that is essential for the enzyme's catalytic activity.

By inhibiting RR, Hydroxyurea prevents the conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates. This depletion of the deoxyribonucleotide pool halts DNA synthesis and repair. In sickle cell disease, the drug's ability to increase fetal hemoglobin (HbF) is thought to be mediated through the activation of the soluble guanylate cyclase pathway and the alteration of erythroid differentiation kinetics, though the exact signaling cascade is still a subject of intense research.

• Dose-Response: There is a clear dose-response relationship between Hydroxyurea and the reduction in white blood cell counts. In sickle cell disease, the increase in HbF typically takes several weeks to months to reach a plateau.
• Onset of Action: For cytoreduction (lowering blood counts), the effect is seen within 7 to 14 days. For sickle cell disease, clinical improvement in crisis frequency may not be apparent for 3 to 6 months.
• Duration of Effect: Once the drug is discontinued, its effects on DNA synthesis reverse quickly (within 24-48 hours), but the elevated HbF levels in red blood cells will persist for the lifespan of those cells (roughly 120 days).

| Parameter | Value |

|---|---|

| Bioavailability | 80% - 100% |

| Protein Binding | 20% - 30% |

| Half-life | 2 - 4 hours |

| Tmax | 1 - 4 hours |

| Metabolism | 60% Hepatic/Intracellular |

| Excretion | Renal 40% (unchanged) |

• Molecular Formula: CH4N2O2
• Molecular Weight: 76.05 g/mol
• Solubility: Highly soluble in water and hot alcohol.
• Structure: A simple hydroxylated derivative of urea. It consists of a urea backbone where one hydrogen atom on one of the nitrogen atoms is replaced by a hydroxyl (-OH) group.

Hydroxyurea is an antimetabolite and a ribonucleotide reductase inhibitor. It is related to other antineoplastic agents like Cytarabine and Gemcitabine, though its clinical application is unique due to its oral bioavailability and specific utility in non-malignant hematology.